Document is current
Any future updates will be listed below
-
Authors
Lehmann, Jens
Bohn, Jan-Paul
Seidl, Claudia
Vorbach, Samuel M.
Willenbacher, Wolfgang
Holzner, Bernhard
Schuler, Markus
- License Information
-
More Information
Article History
Received: 1 April 2025
Accepted: 4 September 2025
First Online: 16 October 2025
Declarations
:
: The study was approved by the ethics committee of the Medical University of Innsbruck (no. 1179/2024) and ethical approval will be obtained for all centers before starting the recruitment process. The study is conducted in accordance with the 1964 declaration of Helsinki.
: BH reports Intellectual Property Rights to the Software CHES used in the study. JL reports consultation for Evaluation Software Development GmbH. WW is an employee of syndena GmbH and received research funding from Amgen, Takeda, BMS-Celgene, Janssen-Cilag, Novartis, Roche, Sanofi, and oncotyrol and received honoraria for participation in steering and safety committees from Amgen, BMS-Celgene, and Morphosys and received honoraria for consultancy from Amgen, Takeda, BMS-Celgene, EUSA Pharma, Gilead, AbbVie, Janssen-Cilag, GSK, Incyte, Kite, Novartis, Morphosys, Merck, Pfizer, Roche, Sandoz, and Sanofi, and received honoraria from Fujimoto and Myelom- und Lymphomselbsthilfe. MKS received institutional research grants and travel expenses from PharmaMar. All other authors report no conflicts of interest.
